Virbac Stock Approaches Its €370 Resistance Two Days Before Earnings Release
Virbac is trading at €367.50 this Tuesday during the session, up 2.23% from the previous close. The veterinary laboratory's stock, which has accumulated a gain of nearly 25.5% over the year, is approaching the announcement of its quarterly revenue in two days.
Current Trading Position
In mid-afternoon, Virbac is priced at €367.50, very close to its identified resistance at €370. The price now slightly exceeds the upper boundary of the Bollinger Bands (€367.40), which could indicate a potential overbought signal: the stock is beyond 100% of the band's amplitude, a situation that may precede a reversion to the mean. However, the RSI at 58 does not yet indicate extreme tension, remaining in a balanced zone. The short-term dynamics are favorable: the price is above both its 50-day moving average (€353.40) and 200-day moving average (€344.89), reflecting a well-established upward trend. Over the past seven days, the gain reached 4.7%. The stock's ability to sustainably break through the €370 threshold will be a critical point to watch to confirm the continuation of this movement or a possible pullback to the €328.50 support level.
Financial Calendar as a Key Factor
The financial calendar is a key factor for the upcoming sessions: Virbac will publish its first-quarter 2026 revenue on April 16, just two days away. This imminent deadline may help explain the increased activity on the stock this Tuesday. The general assembly is scheduled for June 26, followed by the half-year results expected on September 17. In a supportive market environment — the CAC 40 is up 0.79% in the session, the SBF 120 by 0.83% — Virbac outperforms the Paris indices. It is noteworthy that in the healthcare sector, Sanofi is up by 1.17% while UCB is down by 0.18%. The particularly low beta of the stock (0.07) indicates a very limited correlation with the overall market, as Virbac operates under dynamics largely specific to the animal health sector. On the American side, healthcare stocks to watch in the same sector include Lilly (Eli), Johnson & Johnson, and AbbVie.
